Pembrolizumab in combination with chemotherapy meets primary endpoint of progression-free survival (PFS) as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in phase 3 KEYNOTE-355 trial

Based on interim analysis, use with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) demonstrated statistically significant improvement in PFS vs. chemotherapy alone, and trial will continue to evaluate other dual primary endpoint of overall survival.


Biospace Inc.